Abstract | CONTEXT: INTERVENTION:
Rapamycin was administered at an oral dose of 2 mg/d. RESULTS: On the mTOR ( mammalian target of rapamycin) agent rapamycin, he was weaned off all drugs except for the thiazide diuretic and maintained euglycemia with a reduction of circulating insulin levels. He remained euglycemic for the past year with no evidence of tumor progression based on Octreoscan. His quality of life is excellent, and he remains active having recently completed a triathlon. CONCLUSIONS:
Rapamycin may provide a useful means of abrogating tumor growth and controlling hypoglycemia in malignant insulinomas by reducing the malignant beta-cell growth and proliferation as well as inhibiting insulin production.
|
Authors | Matthew E Bourcier, Amanda Sherrod, Margaret DiGuardo, Aaron I Vinik |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 94
Issue 9
Pg. 3157-62
(Sep 2009)
ISSN: 1945-7197 [Electronic] United States |
PMID | 19567519
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Hydrochlorothiazide
- Streptozocin
- buthiazide
- Sirolimus
|
Topics |
- Adenoma, Islet Cell
(drug therapy, pathology)
- Aged
- Aged, 80 and over
- Humans
- Hydrochlorothiazide
(analogs & derivatives, therapeutic use)
- Hypoglycemia
(drug therapy)
- Male
- Pancreatic Neoplasms
(drug therapy, pathology)
- Sirolimus
(therapeutic use)
- Streptozocin
(therapeutic use)
|